Blog
101 posts since 2015. Search, or pick a year.
The Daily Mail University Guide places our AI and Data Science course 2nd in the UK for student support, 4th for student experience and 8th for teaching excellence.
Our paper on automating EMDR therapy is out in Virtual Reality, the Springer journal, and it is open access. In a five-day feasibility study, four of five participants reached subclinical phobia levels.
21 people tried WaveVR at Digital Northants' Merged Futures 8 showcase. 75% said they felt calmer afterwards, on a busy exhibition floor where we weren't sure the calming side would land.
RestoryVR has been recognised as a Digital Northants Champion for work on VR solutions supporting emotion regulation, trauma treatment, and addiction recovery.
We've delivered two VR headsets and WaveVR licences to Inspire, an alcohol and drug service supporting adults, young people, and communities across West Northamptonshire.
WaveVR was invited to SEND IASS North Northants FutureFest at the Corby Cube, where 20 young people experienced a VR mindfulness session. Results showed overwhelmingly positive outcomes.
Prof Mu Mu will present WaveVR at Digital Northants' eighth annual innovation event, demonstrating how immersive VR can support emotional wellbeing.
Early results from our WaveVR pilot programme in schools demonstrate significant improvements in mood, focus, and emotional resilience among young participants.
Our peer-reviewed mixed-method study on VR-based EMDR therapy for specific phobias has been published, demonstrating a 94.1% improvement rate.
Our InnerVoice VR programme for addiction recovery has secured funding from UK Research and Innovation to advance development and begin feasibility testing.
Saffron, a midwifery student at the University of Northampton, took part in our EMDR VR clinical trial to tackle an intense fear of needles and blood – and the results transformed her career.
An overview of our collaboration with Flow Neuroscience and the NHS on home-based transcranial direct current stimulation for depression, and the three journal papers published so far.